Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection
Abstract: Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efcacy in preventing or treating this serious condition and all have side efects to difering degrees. We encourage the continued consideration of the use of the antioxidant and anti-infammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientifc publications have identifed melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral efects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous diferent viruses, including three diferent coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most efective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profle over a wide range of doses and lacks signifcant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially benefcial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2.
Main Authors: | , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Artículo biblioteca |
Language: | eng |
Published: |
Springer
2022-03-25T12:19:36Z
|
Subjects: | CITOQUINAS, INFECCIONES, COVID-19, CORONAVIRUS, SEPSIS, HIPOXIA, |
Online Access: | https://repositorio.uca.edu.ar/handle/123456789/13681 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:ucacris:123456789-13681 |
---|---|
record_format |
koha |
spelling |
oai:ucacris:123456789-136812022-03-26T05:01:20Z Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection Reiter, R. Sharma, Ramaswamy Simko, Fedor Domínguez Rodriguez, Alberto Tesarik, Jan Neel, Richard L. Slominski, Andrzej T. Kleszczynsk, Konrad Martin‑Gimenez, Verna M. Manucha, Walter Cardinali, Daniel Pedro 0000-0001-6763-4225 CITOQUINAS INFECCIONES COVID-19 CORONAVIRUS SEPSIS HIPOXIA Abstract: Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efcacy in preventing or treating this serious condition and all have side efects to difering degrees. We encourage the continued consideration of the use of the antioxidant and anti-infammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientifc publications have identifed melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral efects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous diferent viruses, including three diferent coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most efective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profle over a wide range of doses and lacks signifcant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially benefcial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2. 2022-03-25T12:19:36Z 2022-03-25T12:19:46Z 2022-03-25T12:19:36Z 2022-03-25T12:19:46Z 2022 Artículo Reiter, R. et al. Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection [en línea]. Cellular and Molecular Life Sciences. 2022, 79 (143). doi: 10.1007/s00018-021-04102-3. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/13681 https://repositorio.uca.edu.ar/handle/123456789/13681 10.1007/s00018-021-04102-3 eng Acceso abierto http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Springer Cellular and Molecular Life Sciences. 2022, 79 (143) |
institution |
UCA |
collection |
DSpace |
country |
Argentina |
countrycode |
AR |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-uca |
tag |
biblioteca |
region |
America del Sur |
libraryname |
Sistema de bibliotecas de la UCA |
language |
eng |
topic |
CITOQUINAS INFECCIONES COVID-19 CORONAVIRUS SEPSIS HIPOXIA CITOQUINAS INFECCIONES COVID-19 CORONAVIRUS SEPSIS HIPOXIA |
spellingShingle |
CITOQUINAS INFECCIONES COVID-19 CORONAVIRUS SEPSIS HIPOXIA CITOQUINAS INFECCIONES COVID-19 CORONAVIRUS SEPSIS HIPOXIA Reiter, R. Sharma, Ramaswamy Simko, Fedor Domínguez Rodriguez, Alberto Tesarik, Jan Neel, Richard L. Slominski, Andrzej T. Kleszczynsk, Konrad Martin‑Gimenez, Verna M. Manucha, Walter Cardinali, Daniel Pedro Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection |
description |
Abstract: Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not
consistently demonstrated high efcacy in preventing or treating this serious condition and all have side efects to difering
degrees. We encourage the continued consideration of the use of the antioxidant and anti-infammatory agent, melatonin, as a
countermeasure to a SARS-CoV-2 infection. More than 140 scientifc publications have identifed melatonin as a likely useful
agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic
agent against this condition. Melatonin has pan-antiviral efects and it diminishes the severity of viral infections and reduces
the death of animals infected with numerous diferent viruses, including three diferent coronaviruses. Network analyses,
which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most efective
agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin,
either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death
rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health
care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profle over a wide range
of doses and lacks signifcant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are
summarized. The authors believe that all available, potentially benefcial drugs, including melatonin, that lack toxicity should
be used in pandemics such as that caused by SARS-CoV-2. |
author2 |
0000-0001-6763-4225 |
author_facet |
0000-0001-6763-4225 Reiter, R. Sharma, Ramaswamy Simko, Fedor Domínguez Rodriguez, Alberto Tesarik, Jan Neel, Richard L. Slominski, Andrzej T. Kleszczynsk, Konrad Martin‑Gimenez, Verna M. Manucha, Walter Cardinali, Daniel Pedro |
format |
Artículo |
topic_facet |
CITOQUINAS INFECCIONES COVID-19 CORONAVIRUS SEPSIS HIPOXIA |
author |
Reiter, R. Sharma, Ramaswamy Simko, Fedor Domínguez Rodriguez, Alberto Tesarik, Jan Neel, Richard L. Slominski, Andrzej T. Kleszczynsk, Konrad Martin‑Gimenez, Verna M. Manucha, Walter Cardinali, Daniel Pedro |
author_sort |
Reiter, R. |
title |
Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection |
title_short |
Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection |
title_full |
Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection |
title_fullStr |
Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection |
title_full_unstemmed |
Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection |
title_sort |
melatonin : highlighting its use as a potential treatment for sars‑cov‑2 infection |
publisher |
Springer |
publishDate |
2022-03-25T12:19:36Z |
url |
https://repositorio.uca.edu.ar/handle/123456789/13681 |
work_keys_str_mv |
AT reiterr melatoninhighlightingitsuseasapotentialtreatmentforsarscov2infection AT sharmaramaswamy melatoninhighlightingitsuseasapotentialtreatmentforsarscov2infection AT simkofedor melatoninhighlightingitsuseasapotentialtreatmentforsarscov2infection AT dominguezrodriguezalberto melatoninhighlightingitsuseasapotentialtreatmentforsarscov2infection AT tesarikjan melatoninhighlightingitsuseasapotentialtreatmentforsarscov2infection AT neelrichardl melatoninhighlightingitsuseasapotentialtreatmentforsarscov2infection AT slominskiandrzejt melatoninhighlightingitsuseasapotentialtreatmentforsarscov2infection AT kleszczynskkonrad melatoninhighlightingitsuseasapotentialtreatmentforsarscov2infection AT martingimenezvernam melatoninhighlightingitsuseasapotentialtreatmentforsarscov2infection AT manuchawalter melatoninhighlightingitsuseasapotentialtreatmentforsarscov2infection AT cardinalidanielpedro melatoninhighlightingitsuseasapotentialtreatmentforsarscov2infection |
_version_ |
1756276479006605312 |